The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory and early relapsing diffuse large B-cell lymphoma (DLBCL).
 
Allison Marie Bock
No Relationships to Disclose
 
Raphael Mwangi
No Relationships to Disclose
 
Fatemah Ataei
No Relationships to Disclose
 
Matthew Thorpe
No Relationships to Disclose
 
Matthew J. Maurer
Employment - Exact Sciences (I)
Stock and Other Ownership Interests - Exact Sciences (I)
Consulting or Advisory Role - Adaptive Biotechnologies; Genmab
Research Funding - Bristol-Myers Squibb (Inst); Genmab (Inst); Morphosys (Inst); Roche/Genentech (Inst)
 
Joshua Pritchett
Patents, Royalties, Other Intellectual Property - Intellectual property interests in ongoing development with Mayo Clinic Ventures, patents pending
(OPTIONAL) Uncompensated Relationships - Biofourmis
 
Jacob Tyler Shreve
No Relationships to Disclose
 
Jonas Paludo
Consulting or Advisory Role - Abbvie (Inst)
Research Funding - Biofourmis (Inst); Karyopharm Therapeutics (Inst)
 
Arushi Khurana
No Relationships to Disclose
 
James Robert Cerhan
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene (Inst); Protagonist Therapeutics
Research Funding - Celgene (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genmab (Inst); NanoString Technologies (Inst)
(OPTIONAL) Uncompensated Relationships - Regeneron (Inst)
 
Thomas E. Witzig
Honoraria - Curio Science; Curio Science (Inst)
Consulting or Advisory Role - Salarius Pharmaceuticals; Tornado Therapeutics
Research Funding - Acerta Pharma (Inst); Acrotech Biopharma (Inst); Celgene (Inst); Karyopharm Therapeutics (Inst); Kura Oncology (Inst)
Patents, Royalties, Other Intellectual Property - I am co-inventor on a patent application filed by Mayo Clinic and pending on the combination of CRM1 inhibitors with salicylates. Please note - simply filed - not even close to being granted. (Inst)
 
Thomas Matthew Habermann
Consulting or Advisory Role - Celgene; Kite/Gilead
Research Funding - Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - BeiGene; Incyte; Loxo/Lilly; MorphoSys; Seagen; Tessa Therapeutics
 
Yucai Wang
Employment - Merck (I)
Stock and Other Ownership Interests - Merck (I)
Honoraria - Kite, a Gilead company (Inst)
Consulting or Advisory Role - BeiGene (Inst); Incyte (Inst); Innocare (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Lilly (Inst); Loxo (Inst); TG Therapeutics (Inst)
Research Funding - Genentech (Inst); Genmab (Inst); Incyte (Inst); InnoCare (Inst); Loxo (Inst); MorphoSys (Inst); Novartis (Inst)
 
Jason R. Young
No Relationships to Disclose
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Bantam Pharmaceutical; Celgene (Inst); Debiopharm Group; Genentech (Inst); Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)